CBIO — CRESCENT BIOPHARMA INC.

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying CBIO?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
50
Institutional Conviction
Net distribution · 1 buying vs 1 selling last quarter
37
Macro Tailwind
Macro conditions are a headwind for this sector
38
Why? — Evidence & Confidence ▾

Of 2 tracked investors who changed their CBIO position last quarter, 1 bought and 1 sold (50% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).

Supporting evidence
  • +1 tracked investor added or increased positions last quarter (George Soros)
  • +3 tracked investors reported holding CBIO at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.

About CRESCENT BIOPHARMA INC. (CBIO)

CRESCENT BIOPHARMA INC. (CBIO) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Izzy Englander (Millennium Management), valued at $7M. Across recent filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in CBIO

67
/100
Institutional Accumulation
Added / Increased2
Reduced0
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track CBIO

20
/100
Emerging Interest
3investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

CBIO Ownership Composition

How CRESCENT BIOPHARMA INC. is held across tracked investor types, based on reported 13F positions.

Dominant Type
Multi-Strategy / Quant
96% of tracked value
Institutions
3
tracked investors
Total Reported
$6.6M
combined 13F value
Types2
  • Multi-Strategy / Quant95.6%
  • Macro4.4%
Multi-Strategy / Quant(2)
95.6%
Macro(1)
4.4%

Tracked investors currently reporting CBIO

1 tracked investor has since exited this position — listed separately below.

  • Izzy EnglanderSep 30, 2026
    Millennium Management
    Shares
    84.9K
    Value
    $1.2M
    % Portfolio
    0.00%
  • Ken GriffinSep 30, 2026
    Citadel Advisors
    Shares
    349.7K
    Value
    $5.1M
    % Portfolio
    0.00%
  • George SorosSep 30, 2026
    Soros Fund Management
    Shares
    20K
    Value
    $291.8K
    % Portfolio
    0.00%

Previously held CBIO

These investors reported CBIO in an earlier quarter but not in their most recent 13F. Figures below are their last reported position, not a current holding.

InvestorFirmLast reported sharesValue thenLast held
Steve CohenPoint72 Asset Management300K$5.4MJun 30, 2026

Recent activity

Frequently asked questions

How many institutional investors hold CBIO?
3 tracked institutional investors disclosed a position in CBIO (CRESCENT BIOPHARMA INC.) in their most recent 13F filing.
Who is the largest institutional holder of CBIO?
Izzy Englander, Millennium Management, holds the largest disclosed position in CBIO, valued at $7M.
Did institutional ownership of CBIO increase or decrease?
Across recent 13F filings, tracked investors recorded 2 new positions, 0 increased, 0 reduced, and 1 fully exited CBIO.
Where does this CBIO ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.